Radiation Dose Predicts for Biochemical Control in Intermediate-Risk Prostate Cancer Patients Treated With Low-Dose-Rate Brachytherapy

International Journal of Radiation Oncology Biology Physics

Volumn 75, Issue 1, 2009, Pages 16-22

  Ho, Alice Y ^b   Burri, Ryan J ^a   Cesaretti, Jamie A ^a   Stone, Nelson N ^a   Stock, Richard G ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Brachytherapy; Intermediate risk; Prostate cancer

Indexed keywords

BIOCHEMICAL CONTROL; BIOCHEMICAL FAILURE; BIOLOGICALLY EFFECTIVE DOSE; BRACHYTHERAPY; FREEDOM FROM BIOCHEMICAL FAILURES; GLEASON SCORES; HORMONE THERAPY; INTERMEDIATE RISK; LOW DOSE RATE BRACHYTHERAPY; P-VALUES; PROSTATE CANCER; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; RADIATION DOSE; RADIATION THERAPY ONCOLOGY GROUPS; RISK FACTORS; UNIVARIATE ANALYSIS;

DOSIMETRY; ISOTOPES; PATIENT MONITORING; PEELING; RADIOTHERAPY; RISK ANALYSIS;

DISEASES;

GOSERELIN; IODINE 125; ISOTOPE; LEUPRORELIN; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BRACHYTHERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; TREATMENT FAILURE;

ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY; BRACHYTHERAPY; FLUTAMIDE; FOLLOW-UP STUDIES; GOSERELIN; HUMANS; IODINE RADIOISOTOPES; LEUPROLIDE; MALE; NITRILES; PALLADIUM; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOISOTOPES; RADIOTHERAPY DOSAGE; RELATIVE BIOLOGICAL EFFECTIVENESS; TOSYL COMPOUNDS; TREATMENT FAILURE;

EID: 65449131937     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.10.071     Document Type: Article

References (43)

1. Bahnson R.R., Hanks G.E., Huben R.P., et al. NCCN practice guidelines for prostate cancer. Oncology (Williston Park) 14 (2000) 111-119
2. Stone N.N., and Stock R.G. Prostate brachytherapy: Treatment strategies. J Urol 162 (1999) 421-426
3. Zelefsky M.J., Lyass O., Fuks Z., et al. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy. J Clin Oncol 16 (1998) 3380-3385
4. Zagars G.K., Pollack A., and von Eschenbach A.C. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. Cancer 79 (1997) 1370-1380
5. Roach III M., Chen A., Song J., et al. Pretreatment prostate-specific antigen and Gleason score predict the risk of extracapsular extension and the risk of failure following radiotherapy in patients with clinically localized prostate cancer. Semin Urol Oncol 18 (2000) 108-114
6. Potters L., Klein E.A., Kattan M.W., et al. Monotherapy for stage T1-T2 prostate cancer: Radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol 71 (2004) 29-33
7. Kupelian P.A., Potters L., Khuntia D., et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys 58 (2004) 25-33
8. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
9. Brachman D.G., Thomas T., Hilbe J., et al. Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: Results from a single practice. Int J Radiat Oncol Biol Phys 48 (2000) 111-117
10. Stock R.G., Cahlon O., Cesaretti J.A., et al. Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys 59 (2004) 1352-1359
11. Sylvester J.E., Grimm P.D., Blasko J.C., et al. 15-Year biochemical relapse free survival in clinical stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy: Seattle experience. Int J Radiat Oncol Biol Phys 67 (2007) 57-64
12. Lee L.N., Stock R.G., and Stone N.N. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 52 (2002) 444-452
13. D'Amico A.V., Schultz D., Loffredo M., et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA 284 (2000) 1280-1283
14. Merrick G.S., Wallner K.E., and Butler W.M. Minimizing prostate brachytherapy-related morbidity. Urology 62 (2003) 786-792
15. Merrick G.S., Butler W.M., Wallner K.E., et al. Impact of supplemental external beam radiotherapy and/or androgen deprivation therapy on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 61 (2005) 32-43
16. Blasko J.C., Grimm P.D., Sylsvester J.E., et al. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol 57 (2000) 273-278
17. Grimm P.D., Blasko J.C., Sylvester J.E., et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 51 (2001) 31-40
18. Critz F.A. A standard definition of disease freedom is needed for prostate cancer: Undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition. J Urol 167 (2002) 1310-1313
19. Dattoli M., Wallner K., True L., et al. Long-term outcomes after treatment with external beam radiation therapy and palladium 103 for patients with higher risk prostate carcinoma: Influence of prostatic acid phosphatase. Cancer 97 (2003) 979-983
20. Blasko J.C., Grimm P.D., Sylvester J.E., et al. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 46 (2000) 839-850
21. Merrick G.S., Butler W.M., Wallner K.E., et al. The impact of primary Gleason grade on biochemical outcome following brachytherapy for hormone-naive Gleason score 7 prostate cancer. Cancer J 11 (2005) 234-240
22. Potters L., Morgenstern C., Calugaru E., et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 173 (2005) 1562-1566
23. Khaksar S.J., Langley S.E., Lovell D., et al. Interstitial low dose rate brachytherapy for prostate cancer-A focus on intermediate- and high-risk disease. Clin Oncol (R Coll Radiol) 18 (2006) 513-518
24. Zelefsky M.J., Hollister T., Raben A., et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 47 (2000) 1261-1266
25. American Joint Committee on Cancer. AJCC cancer staging manual. 6th ed. (2002), Springer-Verlag, Chicago
26. Stock R.G., Stone N.N., Wesson M.F., et al. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys 32 (1995) 219-225
27. Stone N.N., Ramin S.A., Wesson M.F., et al. Laparoscopic pelvic lymph node dissection combined with real-time interactive transrectal ultrasound guided transperineal radioactive seed implantation of the prostate. J Urol 153 (1995) 1555-1560
28. Nath R., Anderson L.L., Luxton G., et al. Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med Phys 22 (1995) 209-234
29. Beyer D., Nath R., Butler W., et al. American brachytherapy society recommendations for clinical implementation of NIST-1999 standards for (103)palladium brachytherapy. The Clinical Research Committee of the American Brachytherapy Society. Int J Radiat Oncol Biol Phys 47 (2000) 273-275
30. Stock R.G., Stone N.N., Tabert A., et al. A dose-response study for I-125 prostate implants. Int J Radiat Oncol Biol Phys 41 (1998) 101-108
31. Stock R.G., Stone N.N., Lo Y.C., et al. Postimplant dosimetry for (125)I prostate implants: Definitions and factors affecting outcome. Int J Radiat Oncol Biol Phys 48 (2000) 899-906
32. Potters L., Cao Y., Calugaru E., et al. A comprehensive review of CT-based dosimetry parameters and biochemical control in patients treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 50 (2001) 605-614
33. Barendsen G.W. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys 8 (1982) 1981-1997
34. Thames Jr. H.D., Withers H.R., Peters L.J., et al. Changes in early and late radiation responses with altered dose fractionation: implications for dose-survival relationships. Int J Radiat Oncol Biol Phys 8 (1982) 219-226
35. Fowler J.F. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol 62 (1989) 679-694
36. Brenner D.J., and Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43 (1999) 1095-1101
37. Fowler J., Chappell R., and Ritter M. Is alpha/beta for prostate cancer really low?. Int J Radiat Oncol Biol Phys 50 (2001) 1021-1031
38. Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52 (2002) 6-13
39. Wang J.Z., Guerrero M., and Li X.A. How low is the alpha/beta ratio for prostate cancer?. Int J Radiat Oncol Biol Phys 55 (2003) 194-203
40. Jani A.B., Hand C.M., Lujan A.E., et al. Biological effective dose for comparison and combination of external beam and low-dose rate interstitial brachytherapy prostate cancer treatment plans. Med Dosim 29 (2004) 42-48
41. Stock R.G., Stone N.N., Cesaretti J.A., et al. Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results. Int J Radiat Oncol Biol Phys 64 (2006) 527-533
42. Roach III M., Hanks G., Thames Jr. H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65 (2006) 965-974
43. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481